Effect of cytoskeleton inhibitors on deadhesion kinetics of HepG2 cells on biomimetic surface.
Cytochalasin-D (Cyto-D) and latrunculin-A (Lat-A) are known inhibitors of actin microfilaments and adversely affect the physiological functions of anchorage-dependent cells. Alternatively, doxorubicin (Dox), a chemotherapeutic drug is known to induce apoptosis and cell detachment of tumor cells. However, the intricate interplay between drug administration, cytoskeletal rearrangement and biophysical responses of live cells on immobilized layer of extracellular matrix (ECM) protein remains unknown. In this study, the deadhesion kinetics and actin remodeling of live HepG2 cells following the addition of the three drugs are probed with confocal reflectance interference contrast microscopy (C-RICM) and fluorescence confocal microscopy. First, it is shown that the reduction in two-dimensional spread area of HepG2 cells is 10.5%, 15.4% and 21.9% under the influence of 5 microM of Lat-A, Cyto-D and Dox, respectively. Secondly, C-RICM demonstrates the recession of strong adhesion contact against time of cell seeding upon the addition of the three drugs. Thirdly, the initial cell detachment rate and extent of reduction in the degree of cell deformation (a/R) are dependent on both the drug types and concentration. Lastly, oscillation-like responses of a/R and adhesion energy are uniquely found in Lat-A induced cell detachment. Overall, our biophysical approaches have been proven as a highly quantitative platform for elucidating the interfacial properties of adherent cells on biomimetic surfaces under cytoskeleton disruption.
Feng
Zhiqin
Z
School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore 639798, Singapore.
Chen
Beiyi
B
Tang
Shiue-Cheng
SC
Liao
Kin
K
Chen
Wei Ning
WN
Chan
Vincent
V
D000199:Actins / Q000378:metabolism; D040761:Biomimetic Materials / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D015638:Cytochalasin D / Q000494:pharmacology*; D003599:Cytoskeleton / Q000187:drug effects*; D004317:Doxorubicin / Q000494:pharmacology*; D005455:Fluorescent Antibody Technique; D056945:Hep G2 Cells; D006801:Humans; D007700:Kinetics; D013499:Surface Properties / Q000187:drug effects; D053778:Thiazolidines / Q000494:pharmacology*; D013997:Time Factors
D000199:Actins; D019086:Bridged Bicyclo Compounds, Heterocyclic; D053778:Thiazolidines; D015638:Cytochalasin D; D004317:Doxorubicin; D003094:Collagen; C037067:latrunculin A